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Abstract 
Background:  Prior to the recognition of C-Kit mutations, GIST were most commonly classified as leiomyoma, 
leiomyosarcoma, leiomyoblastoma or Autonomic nervous system gastrointestinal tumor. This is why, for the 
accurate histologic diagnosis of these tumors, it is necessary to record the C-Kit mutation and to identify some 
other molecular markers that help in differential diagnosis. C-Kit mutation detection is a criterion for 
morphologic diagnosis and also it serves as a predictive factor for determining the therapy with Imatinib (Glivec) 
if it is present in these tumors.Objectives: Evaluation of 49 cases of C-Kit mutations and differential diagnosis 
assessment by IHC examinations.Material and Methods: The study is a retrospective cohort type. 49 patients 
was evaluated the C-Kit mutation and further IHC examinations for differential diagnosis with other similar 
lesions. For this purpose the immunoreactivity for CD117, CD34, Actin, Desmin, S100 was evaluated. In these 
cases, the proliferative index with Ki67 was also evaluated as a prognostic factor together with the tumor 
diameter and presence or not of necrosis.Results: In the cases studied the presence of c-kit mutation (CD117 
positive) was detected in 97% of the examined cases, CD34 was found positive in 77% of the examined cases, 
SMA was found positive in 34% of the examined cases, Desmin was found positive in 17% of the examined 
cases, S100 was found positive in 7% of the examined cases. Ki67 resulted to be on average 17.6% in cases with 
mitotic index> 5/50 HPF and on average 5.7% in cases with mitotic index <5/50% HPF Conclusions: Most of 
the mesenchymal tumors in the gastrointestinal system are Gastrointestinal Stromal type. This tumor is 
diagnosed in most cases if C-Kit mutation (positive immunoreactivity for CD117) is identified. Other 
immunostains like CD34, SMA, Desmin,  S100, help in the diagnose by differentiating this tumor from other 
histologically similar lesions. Proliferative index determination by Ki67 serves for the differentiation of these 
tumors into two prognostic categories. 
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Introduction 
Gastrointestinal Stromal Tumors (GIST) became a clear histological diagnostic entity in 1998, when it was 
found that nearly all GIST-s present mutations in the KIT gene. Prior to recognizing KIT mutations, GIST were 
most commonly classified as leiomyoma, leiomyosarcoma, leiomyoblastoma and as autonomic nervous system 
gastrointestinal tumors. Other mesenchymal tumors that constitute the differential diagnosis of GIST are 
precisely these tumors, as well as fibromatosis, angiomatous, neuronal, neuroendocrine tumors, and 
undifferentiated sarcoma, or carcinoma and melanoma metastases. That’s why, for the accurate histologic 
diagnosis of this tumor, which is thought to derive from the progenitor cells of the "Interstitial Cells of Cajal", it 
is necessary to record the C-Kit Mutation and to identify some other molecular markers that help in differential 
diagnosis such as CD34, SMA, Desmin and S100. Tyrosine-kinase Inhibitor receptors such as imatinib mesylate 
and others of the younger generations such as sunitinib are effective in treating GIST. Thus, proper diagnosis of 
these tumors is important to provide adequate and effective therapy. For this reason, the positive 
immunereactivity of the c-kit has become an essential tool in evaluating neoplastic mesenchymal lesions of GI 
tract and for establishing GIST diagnosis (1). However, 4% to 15% of GIST does not stain with c-kit, and the 
morphology of these tumors is often similar to other mesenchymal tumors which constitute the differential 
diagnosis. Thus, Immunochemistry is an essential diagnostic examination in evaluating the neoplastic 
mesenchymal lesions of GI tract (1-4). On the other hand, the determination of proliferative index with Ki67, 
apart from the determination of maximal diameter tumor and the presence or absence of necrosis, divides these 
tumors into different prognostic categories. 
 
Material and Methods 
The tissue samples taken during the surgical intervents were fixed 10% buffered formalin for about 48 hours. 
From the examiner pathologist, measurements of the tumor dimensions were made and the cutting surface was 
inspected for possible macroscopic changes and evidence of the lesion on the organ wall. Representative tissue 
samples were taken for histopathologic examination, including continuity from the central area to the peripheral 
area. Selected tissue samples for histopathological examination were placed on tissue blocs and then placed on 
Leica 1020 automatic processor. Histopathologic examination has been performed by diagnosis and 
classification based on the histological type and the histological degree determined by WHO criteria described in 
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the "Blue Book" (5). In the respective microscopic magnification is evaluated the morphology of cells; 
Cellularity; Atypism, mitotic activity who is estimated by the presence of mitosis and is quantified for 50HPF; 
The level of invasion in the organ wall and the presence of necrosis. After evaluating the macroscopic and 
microscopic features described above, the histopathologic diagnosis and classification was made according to 
WHO classification in the "Blue Book" (5- WHO of GI).  
After histological examination, was performed the selection of the most representative paraffin block for 
immunohistochemistry analysis. In all the 49 cases, full sections of the selected paraffin blocks were examined. 
Immunohistochemical staining was done automatically with Ventana Benc Mak XT system where antibodies 
were used according to the specifications presented in Table 1. 
Antibodies Clones Manufacturer Dilution 
CD117 A4502  DAKO 1:250 
CD34 QBEnd10 DAKO 1:50 
SMA 1A4 DAKO 1:100 
Ki-67 MIB-5 DAKO 1:100 
DESMIN D33 DAKO 1:100 
S100 ZO311 DAKO 1:100 
Table 1. Antibodies, clones, manufacturers and dilutions. 
Presentation of the data recorded is based on tables and diagrams. The processing of data is based on the 
SPSS 20 statistical program. 
 
Results: 
In 44 cases diagnosed as GIST after IHC examinations, the male-female ratio was 1.44: 1. Below this report is 
presented graphically. The age interval in our study was 32-81 years. The average age turned out to be 61.5 years 
and the average age by gender was 63.2 for males and 59.5 for females. 
 
Figure 1: Gender distribution of cases diagnosed with GIST.   Table 2: Age as per gender. 
The most frequent localization resulted to be stomach with 59% of cases, followed by intestine with 32% of 
cases. 
 
Figure 2: Distribution of cases by location                           Figure 3: Case distribution according to mitotic index 
The following graph was processed by analyzing the mitotic indexes. 75% of the cases resulted with low 
mitotic index, 22% with high mitotic index and in 3% of cases there were no mitosis. The average tumor 
diameter resulted to be 6.9 cm. 
CD117 was applied in 82% of cases and resulted positive in 97% .CD34 was applied in 80% of cases and 
resulted positive in 77% of them. Actin was reviewed in 73% of cases and resulted positive in 34% of them. 
S100 was applied in 64% of cases and resulted positive in 7% of them. Desmin was applied in 68% of cases and 
resulted positive in 17% of them.  
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Figure 4: Distribution of immune-markers in examined cases  
The average of proliferative index Ki 67 was 12%. The correlation between the proliferative index Ki67 and 
the mitotic index was analyzed. Ki67 resulted to be on average 17.6 in cases with mitotic index> 5/50 HPF. Ki67 
resulted to be on average of 5.7 in cases with mitotic index <5/50 HPF. At the end 89.8% of the morphologically 
suspected diagnoses for GIST in Hematoxylin-Eosin stain resulted Gist in the final diagnosis after IHC 
examinations. The most common histopathologic diagnoses  encountered  were GIST with low malignancy in 
50% of cases and GIST with intermediate malignity in 31% of cases. 75% of cases resulted with low mitotic 
index, 22% with high mitotic index and in 3% of cases no mitosis were observed.  
 
Figure 5. Distribution of Gist according to malignant potential. 
 
Discussion 
GIST-s, gastrointestinal leiomyoma or leiomyosarcoma, schwannoma, local extension of a retroperitoneal 
primary undifferentiated liposarcoma, benign and malignant vascular tumors, intra-abdominal fibromatosis 
(desmoid tumor), carcinoid tumor with a fusiform morphology, and melanoma metastasis with fusiform 
morphology, or carcinoma are the predominant tumors that need to be considered in the differential diagnosis. 
Most of these tumors can be accurately evaluated based on accurate clinical data and careful microscopy 
examinations fulfilled by proper immunohistochemical stains, and sometimes even ultrastructural data and 
molecular biology examinations. 
The differential diagnosis of GIST from primary tumors of smooth muscle may sometimes be difficult. 
Although the positive immunoreactivity for CD117 in GIST should greatly facilitate Gist-s distinction from 
primary smooth muscule tumors. In 5% of cases CD117 (c-kit) may result negative in immunohistochemistry(1-
5), in GISTs with extreme myoid differentiation, thus making very difficult the distinction between the two 
entities with the current techniques. In this case the diagnosis remains largely based on the results of CD34, 
SMA and Desmin and may often not be totally definitive with current techniques. 
Another potential problem are GISTs with epithelioid morphology, with negative immunoreactivity for 
CD117 and CD34, which may be encumbered by a metastasis of melanoma with a primary non-target focus. In 
this case, S100 can  be found that are commonly found positive in melanoma and more rarely in GIST (4). 
Proliferative index Ki67 correlates in our study with the mitotic index in these tumors and thus  serves for the 
differentiation of these tumors into two categories, which may be also prognostic categories.  
 
Conclusions 
Gastrointestinal  stromal  tumors  (GIST)  are  the  most    common    primary    mesenchymal neoplasms  of  the  
GI  tract. These tumors are found mostly in stomach and small intestine. This tumor is mostly diagnosed if C-Kit 
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mutation (positive immunoreactivity for CD117) is identified but positive immunoreactivity for Cd34 can help 
the diagnosis especially in cases with negative CD117. Other Immunostains as SMA, Desmin, S100, help in the 
differential diagnosis with other lesions with similar histologic patterns. Proliferative index Ki67 correlates with 
the mitotic index and helps identifying prognostic groups. 
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